There are a lot investors doubting the recently created AbbVie (NYSE:ABBV) and its blockbuster arthritis drug, Humira. That's largely because Humira makes up such an overwhelming percentage of AbbVie's earnings, and investors are watching closely to see how the company positions itself ahead of the drug's patent expiration in a few years. In this video, Motley Fool health care bureau chief Brenton Flynn discusses one of his takeaways from AbbVie's presentation at this year's JPMorgan conference on health care, highlighting some surprising areas where the company will be pushing for Humira growth.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 57% 38%
17+ years 350% 95%
Stock Advisor launched in February of 2002. Returns as of 12/09/2019.Join Stock Advisor